Loading…
Next Generation Weight Loss Drugs for the Prevention of Cancer?
Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA)...
Saved in:
Published in: | Cancer control 2024-01, Vol.31, p.10732748241241158-10732748241241158 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c429t-ced0f8e705516486c2ba239c24d7f0c3755034e4c6563db1ba9273062ad5c8d33 |
container_end_page | 10732748241241158 |
container_issue | |
container_start_page | 10732748241241158 |
container_title | Cancer control |
container_volume | 31 |
creator | Carbonell, Chantelle Mathew Stephen, Mariet Ruan, Yibing Warkentin, Matthew T. Brenner, Darren R. |
description | Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity-related cancers.
Purpose: To investigate the potential of next generation weight loss drugs (NGWLD) like GLP-1RA in population-level chemoprevention.
Research Design: We used the OncoSim microsimulation tool to estimate the population-level reductions in obesity and the potentially avoidable obesity-related cancers in Canada over the next 25 years.
Results: We estimated a total of 71 281 preventable cancers by 2049, with 36 235 and 35 046 cancers prevented for females and males, respectively. Among the 327 254 total projected cancer cases in 2049, 1.3% are estimated to be preventable through intervention with NGWLD.
Conclusions: Pharmacologic intervention is not the ideal solution for the obesity-related cancer crisis. However, these agents and subsequent generations provide an additional tool to rapidly reduce body weight and adiposity in populations that have been extremely challenging to reduce weight with standard diet and exercise approaches. Additional research is needed around approaches to prevent initial weight gain and maintain long-term weight loss. |
doi_str_mv | 10.1177/10732748241241158 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4755900f206b409cb8897ebd38f7b5da</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_10732748241241158</sage_id><doaj_id>oai_doaj_org_article_4755900f206b409cb8897ebd38f7b5da</doaj_id><sourcerecordid>3149771657</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-ced0f8e705516486c2ba239c24d7f0c3755034e4c6563db1ba9273062ad5c8d33</originalsourceid><addsrcrecordid>eNp1kV1rFDEUhkNR2lr9Ab0pA954M_XkO7kqZdVaWLQXFS9DJjmznWV30iYzRf-9abdWUIRAQvKc5yR5CTmmcEqp1u8paM60MEzQOqg0e-SQSqZaxqV9Udf1vH0ADsirUtYADAQX--SAG0mVFuyQnH3BH1NzgSNmPw1pbL7jsLqZmmUqpfmQ51Vp-pSb6Qabq4z3OD5CqW8WfgyYz16Tl73fFHzzNB-Rb58-Xi8-t8uvF5eL82UbBLNTGzBCb1CDrI2FUYF1nnEbmIi6h8C1lMAFiqCk4rGjnbdMc1DMRxlM5PyIXO68Mfm1u83D1uefLvnBPW6kvHI-T0PYoBNVZgF6BqoTYENnjNXYRW563cnoq-vdznWb092MZXLboQTcbPyIaS6OWS0AhBSqom__QtdpzmN9qeNUWK2pkrpSdEeFXL8tY_98QQruISn3T1K15uTJPHdbjM8Vv6OpwOkOKH6Ff9r-3_gLM3yXTg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3149771657</pqid></control><display><type>article</type><title>Next Generation Weight Loss Drugs for the Prevention of Cancer?</title><source>Publicly Available Content Database</source><source>Sage Journals GOLD Open Access 2024</source><source>PubMed Central</source><creator>Carbonell, Chantelle ; Mathew Stephen, Mariet ; Ruan, Yibing ; Warkentin, Matthew T. ; Brenner, Darren R.</creator><creatorcontrib>Carbonell, Chantelle ; Mathew Stephen, Mariet ; Ruan, Yibing ; Warkentin, Matthew T. ; Brenner, Darren R.</creatorcontrib><description>Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity-related cancers.
Purpose: To investigate the potential of next generation weight loss drugs (NGWLD) like GLP-1RA in population-level chemoprevention.
Research Design: We used the OncoSim microsimulation tool to estimate the population-level reductions in obesity and the potentially avoidable obesity-related cancers in Canada over the next 25 years.
Results: We estimated a total of 71 281 preventable cancers by 2049, with 36 235 and 35 046 cancers prevented for females and males, respectively. Among the 327 254 total projected cancer cases in 2049, 1.3% are estimated to be preventable through intervention with NGWLD.
Conclusions: Pharmacologic intervention is not the ideal solution for the obesity-related cancer crisis. However, these agents and subsequent generations provide an additional tool to rapidly reduce body weight and adiposity in populations that have been extremely challenging to reduce weight with standard diet and exercise approaches. Additional research is needed around approaches to prevent initial weight gain and maintain long-term weight loss.</description><identifier>ISSN: 1073-2748</identifier><identifier>EISSN: 1526-2359</identifier><identifier>DOI: 10.1177/10732748241241158</identifier><identifier>PMID: 38516742</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adipose tissue ; Anti-Obesity Agents - therapeutic use ; Body weight ; Body weight loss ; Cancer ; Drug development ; Female ; Humans ; Male ; Neoplasms - epidemiology ; Neoplasms - prevention & control ; Obesity ; Obesity - complications ; Obesity - epidemiology ; Research design ; Risk Factors ; Weight control ; Weight Loss</subject><ispartof>Cancer control, 2024-01, Vol.31, p.10732748241241158-10732748241241158</ispartof><rights>The Author(s) 2024</rights><rights>The Author(s) 2024. This work is licensed under the Creative Commons Attribution License https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c429t-ced0f8e705516486c2ba239c24d7f0c3755034e4c6563db1ba9273062ad5c8d33</cites><orcidid>0009-0004-6384-3424</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/10732748241241158$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3149771657?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,21966,25753,27853,27924,27925,37012,37013,44590,44945,45333</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38516742$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carbonell, Chantelle</creatorcontrib><creatorcontrib>Mathew Stephen, Mariet</creatorcontrib><creatorcontrib>Ruan, Yibing</creatorcontrib><creatorcontrib>Warkentin, Matthew T.</creatorcontrib><creatorcontrib>Brenner, Darren R.</creatorcontrib><title>Next Generation Weight Loss Drugs for the Prevention of Cancer?</title><title>Cancer control</title><addtitle>Cancer Control</addtitle><description>Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity-related cancers.
Purpose: To investigate the potential of next generation weight loss drugs (NGWLD) like GLP-1RA in population-level chemoprevention.
Research Design: We used the OncoSim microsimulation tool to estimate the population-level reductions in obesity and the potentially avoidable obesity-related cancers in Canada over the next 25 years.
Results: We estimated a total of 71 281 preventable cancers by 2049, with 36 235 and 35 046 cancers prevented for females and males, respectively. Among the 327 254 total projected cancer cases in 2049, 1.3% are estimated to be preventable through intervention with NGWLD.
Conclusions: Pharmacologic intervention is not the ideal solution for the obesity-related cancer crisis. However, these agents and subsequent generations provide an additional tool to rapidly reduce body weight and adiposity in populations that have been extremely challenging to reduce weight with standard diet and exercise approaches. Additional research is needed around approaches to prevent initial weight gain and maintain long-term weight loss.</description><subject>Adipose tissue</subject><subject>Anti-Obesity Agents - therapeutic use</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Cancer</subject><subject>Drug development</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasms - epidemiology</subject><subject>Neoplasms - prevention & control</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - epidemiology</subject><subject>Research design</subject><subject>Risk Factors</subject><subject>Weight control</subject><subject>Weight Loss</subject><issn>1073-2748</issn><issn>1526-2359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kV1rFDEUhkNR2lr9Ab0pA954M_XkO7kqZdVaWLQXFS9DJjmznWV30iYzRf-9abdWUIRAQvKc5yR5CTmmcEqp1u8paM60MEzQOqg0e-SQSqZaxqV9Udf1vH0ADsirUtYADAQX--SAG0mVFuyQnH3BH1NzgSNmPw1pbL7jsLqZmmUqpfmQ51Vp-pSb6Qabq4z3OD5CqW8WfgyYz16Tl73fFHzzNB-Rb58-Xi8-t8uvF5eL82UbBLNTGzBCb1CDrI2FUYF1nnEbmIi6h8C1lMAFiqCk4rGjnbdMc1DMRxlM5PyIXO68Mfm1u83D1uefLvnBPW6kvHI-T0PYoBNVZgF6BqoTYENnjNXYRW563cnoq-vdznWb092MZXLboQTcbPyIaS6OWS0AhBSqom__QtdpzmN9qeNUWK2pkrpSdEeFXL8tY_98QQruISn3T1K15uTJPHdbjM8Vv6OpwOkOKH6Ff9r-3_gLM3yXTg</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Carbonell, Chantelle</creator><creator>Mathew Stephen, Mariet</creator><creator>Ruan, Yibing</creator><creator>Warkentin, Matthew T.</creator><creator>Brenner, Darren R.</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0009-0004-6384-3424</orcidid></search><sort><creationdate>20240101</creationdate><title>Next Generation Weight Loss Drugs for the Prevention of Cancer?</title><author>Carbonell, Chantelle ; Mathew Stephen, Mariet ; Ruan, Yibing ; Warkentin, Matthew T. ; Brenner, Darren R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-ced0f8e705516486c2ba239c24d7f0c3755034e4c6563db1ba9273062ad5c8d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adipose tissue</topic><topic>Anti-Obesity Agents - therapeutic use</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Cancer</topic><topic>Drug development</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasms - epidemiology</topic><topic>Neoplasms - prevention & control</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - epidemiology</topic><topic>Research design</topic><topic>Risk Factors</topic><topic>Weight control</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carbonell, Chantelle</creatorcontrib><creatorcontrib>Mathew Stephen, Mariet</creatorcontrib><creatorcontrib>Ruan, Yibing</creatorcontrib><creatorcontrib>Warkentin, Matthew T.</creatorcontrib><creatorcontrib>Brenner, Darren R.</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>Cancer control</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carbonell, Chantelle</au><au>Mathew Stephen, Mariet</au><au>Ruan, Yibing</au><au>Warkentin, Matthew T.</au><au>Brenner, Darren R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Next Generation Weight Loss Drugs for the Prevention of Cancer?</atitle><jtitle>Cancer control</jtitle><addtitle>Cancer Control</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>31</volume><spage>10732748241241158</spage><epage>10732748241241158</epage><pages>10732748241241158-10732748241241158</pages><issn>1073-2748</issn><eissn>1526-2359</eissn><abstract>Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity-related cancers.
Purpose: To investigate the potential of next generation weight loss drugs (NGWLD) like GLP-1RA in population-level chemoprevention.
Research Design: We used the OncoSim microsimulation tool to estimate the population-level reductions in obesity and the potentially avoidable obesity-related cancers in Canada over the next 25 years.
Results: We estimated a total of 71 281 preventable cancers by 2049, with 36 235 and 35 046 cancers prevented for females and males, respectively. Among the 327 254 total projected cancer cases in 2049, 1.3% are estimated to be preventable through intervention with NGWLD.
Conclusions: Pharmacologic intervention is not the ideal solution for the obesity-related cancer crisis. However, these agents and subsequent generations provide an additional tool to rapidly reduce body weight and adiposity in populations that have been extremely challenging to reduce weight with standard diet and exercise approaches. Additional research is needed around approaches to prevent initial weight gain and maintain long-term weight loss.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>38516742</pmid><doi>10.1177/10732748241241158</doi><orcidid>https://orcid.org/0009-0004-6384-3424</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1073-2748 |
ispartof | Cancer control, 2024-01, Vol.31, p.10732748241241158-10732748241241158 |
issn | 1073-2748 1526-2359 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_4755900f206b409cb8897ebd38f7b5da |
source | Publicly Available Content Database; Sage Journals GOLD Open Access 2024; PubMed Central |
subjects | Adipose tissue Anti-Obesity Agents - therapeutic use Body weight Body weight loss Cancer Drug development Female Humans Male Neoplasms - epidemiology Neoplasms - prevention & control Obesity Obesity - complications Obesity - epidemiology Research design Risk Factors Weight control Weight Loss |
title | Next Generation Weight Loss Drugs for the Prevention of Cancer? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A33%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Next%20Generation%20Weight%20Loss%20Drugs%20for%20the%20Prevention%20of%20Cancer?&rft.jtitle=Cancer%20control&rft.au=Carbonell,%20Chantelle&rft.date=2024-01-01&rft.volume=31&rft.spage=10732748241241158&rft.epage=10732748241241158&rft.pages=10732748241241158-10732748241241158&rft.issn=1073-2748&rft.eissn=1526-2359&rft_id=info:doi/10.1177/10732748241241158&rft_dat=%3Cproquest_doaj_%3E3149771657%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c429t-ced0f8e705516486c2ba239c24d7f0c3755034e4c6563db1ba9273062ad5c8d33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3149771657&rft_id=info:pmid/38516742&rft_sage_id=10.1177_10732748241241158&rfr_iscdi=true |